Novo Nordisk initiates trial with obesity-treating tablet

On Wednesday afternoon, Novo Nordisk announced that the molecule semaglutide will soon be tested in tablet form in a phase IIIa trial to treat obesity.

Photo: Novo Nordisk / PR

Novo Nordisk plans to initiate a new phase IIIa trial program against obesity with the firm's molecule semaglutide, according to a press release on Wednesday afternoon.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs